Page 51 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

95. Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 1989;320:271-7.
96. de Marco R, Marcon A, Jarvis D, et al. Prognostic factors of asthma severity: a 9-year international prospective cohort study. J Allergy Clin Immunol 2006; 117:1249-56.
97. Naqvi M, Choudhry S, Tsai HJ, et al. Association between IgE levels and asthma severity among African American, Mexican, and Puerto Rican patients with asthma. J Allergy Clin Immunol 2007;120:137-43.
98. den Otter I, Silva LF, Carvalho AL, et al. High-affinity immunoglobulin E receptor expression is increased in large and small airways in fatal asthma. Clin Exp Allergy 2010; 40:1473-81.
99. Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med 2006;354:2689-95.
100. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108:184-90.
101. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011;139:28-35.
102. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001;18:254-61.
103. O’Driscoll BR, Powell G, Chew F, et al. Comparison of skin prick tests with specific serum immunoglobulin E in the diagnosis of fungal sensitization in patients with severe asthma. Clin Exp Allergy 2009; 39:1677-83.
104. Schwartz HJ, Citron KM, Chester EH, et al. A comparison of the prevalence of sensitization to Aspergillus antigens among asthmatics in Cleveland and London. J Allergy Clin Immunol 1978;62:9-14.
105. Zureik M, Neukirch C, Leynaert B, et al. Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey. BMJ 2002;325:411-4.
106. Fairs A, Agbetile J, Hargadon B, et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med 2010; 182:1362-8.
107. Ward GW Jr., Woodfolk JA, Hayden ML, et al. Treatment of late-onset asthma with fluconazole. J Allergy Clin Immunol 1999;104:541-6.
108. Denning DW, O’Driscoll BR, Powell G, et al. Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: The Fungal Asthma Sensitization Trial (FAST) study. Am J Respir Crit Care Med 2009;179:11-8.
109. Gore RB. The utility of antifungal agents for asthma. Curr Opin Pulm Med 2010;16:36-41.
110. Rackemann FM. A working classification of asthma. Am J Med 1947;3:601-6.
111. Mascia K, Haselkorn T, Deniz YM, et al. Aspirin sensitivity and severity of asthma: evidence for irreversible airway obstruction in patients with severe or difficult-to-treat asthma. J Allergy Clin Immunol 2005;116:970-5.
112. Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-83.
113. Szczeklik A, Nizankowska E. Clinical features and diagnosis of aspirin induced asthma. Thorax 2000;55(2):S42-S44.
114. Delclaux C, Malinvaud D, Chevalier-Bidaud B, et al. Nitric oxide evaluation in upper and lower respiratory tracts in nasal polyposis. Clin Exp Allergy 2008;38:1140-7.
115. Ten Brinke A, Grootendorst DC, Schmidt JT, et al. Chronic sinusitis in severe asthma is related to sputum eosinophilia. J Allergy Clin Immunol 2002;109:621-6.
116. van Veen IH, Ten Brinke A, Gauw SA, et al. Consistency of sputum eosinophilia in difficult-to-treat asthma: a 5-year follow-up study. J Allergy Clin Immunol 2009;124:615-7, 617.
117. Bresciani M, Paradis L, Des Roches A, et al. Rhinosinusitis in severe asthma. J Allergy Clin Immunol 2001;107:73-80.
118. Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 2007;119:405-13.
Current treatment of severe asthma
49
2